A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti. BCMA-directed cell therapy ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat blood cancer multiple myeloma, which brought in $406 million in sales ...

The research team, led by Professors Kwong Yok-lam (front right) and Eric Tse Wai-choi (front left), successfully utilises ...

In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...

This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. The CARVYKTI ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, ...

Zevor-cel was approved by China's National Medical Products Administration (NMPA). <li /> As of December 31, 2024, ...

The results of the IIT proof-of-concept study of an allogeneic BCMA-targeting CAR T-cell product candidate CT0590, which deploys the THANK-uCAR ® technology platform, were presented as a poster ...